Are you Dr. Rasco?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 106 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4383 Medical Dr
Fl 3
San Antonio, TX 78229Phone+1 210-593-5700Fax+1 210-593-5992
Summary
- Dr. Drew Rasco, MD is an oncologist in San Antonio, Texas. He is currently licensed to practice medicine in Texas and Georgia. He is affiliated with Methodist Hospital and Northeast Baptist Hospital.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Emory University School of MedicineResidency, Internal Medicine, 2003 - 2006
The University of Texas Health Science Center at San AntonioClass of 2003
Certifications & Licensure
TX State Medical License 2008 - 2026
GA State Medical License 2005 - 2009- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Start of enrollment: 2011 Sep 12
- Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone Start of enrollment: 2013 May 01
- Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Start of enrollment: 2015 Sep 08
- Join now to see all
Publications & Presentations
PubMed
- First-in-human study of 23ME-00610, an antagonistic antibody for genetically validated CD200R1 immune checkpoint, in participants with advanced solid malignancies.Shivaani Kummar, Albiruni Abdul Razak, Scott Laurie, Dylan M Glatt, Sariah Kell
Cancer Research Communications. 2024-12-09 - 1 citationsComprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora
Cancer Research. 2024-08-01 - A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing
Investigational New Drugs. 2024-06-01
Press Mentions
Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific ProgramMay 29th, 2020
START & Sarah Cannon Partner to Advance Therapies for Patients with CancerJanuary 16th, 2018
MEDIAN Technologies and START Expand Relationship to Three New Centers in Grand Rapids, MI and Madrid, SpainJune 30th, 2016- Join now to see all
